Valued at $101.7 billion by market cap, CME Group Inc. (CME) operates as the world’s leading derivatives marketplace. The Chicago-based derivatives exchange offers the widest range of global benchmark products across all major asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate.

Companies worth $10 billion or more are generally referred to as “large-cap stocks,” and CME fits this bill perfectly. Given the company’s dominant position in derivatives markets and wide range of offerings, its valuation above this mark is unsurprising.

CME touched its all-time high of $290.79 on Jun. 2 and is currently trading 4.4% below that peak. Over the past three months alone, CME stock has soared 10.3%, outperforming the industry-focused SPDR S&P Capital Markets ETF’s (KCE) 3.2% gains during the same time frame.

CME’s performance has remained even more impressive over the longer term. CME stock has surged 19.7% on a YTD basis and 36.4% over the past year, significantly outpacing KCE’s 1.9% dip in 2025 and 22.6% returns over the past 52 weeks.

CME stock has traded consistently above its 200-day moving average since August last year and above its 50-day moving average since late January, underscoring its bullish trend.

Despite reporting solid financials, CME Group’s stock prices dipped 1.5% after the release of its Q1 results on Apr. 23. The globe has recently observed a steep spike in macro and geopolitical uncertainties, which has increased the need for hedging business risk. This has led to CME observing broad-based growth across its derivative products based on all asset classes. The company observed a record average daily volume of 29.8 million contracts during the quarter, leading to a 10.4% year-over-year surge in total revenues to a record $1.6 billion. Meanwhile, its adjusted net income increased by an impressive 11.9% year-over-year to more than $1 billion, and its adjusted EPS of $2.80 surpassed the consensus estimates by a small margin.

Following the initial dip, CME Group’s stock remained green for the next 10 trading sessions.

While CME has marginally lagged behind its peer Intercontinental Exchange, Inc.’s (ICE) 20.2% gains on a YTD basis, it has notably outpaced ICE’s 32.9% returns over the past year.

Among the 19 analysts covering the CME stock, the consensus rating is a “Moderate Buy.” As of writing, the stock is trading slightly above its mean price target of $274.61.